An interesting phase III trial looking at options for treating hot flushes in men recieving androgren deprivation for prostate cancer. The short - all reduced hot flushes, but cyproterone and medroxyprogesterone were superior. The authors conclude that medroxyprogesterone 20mg daily is the perferred treatment, as cyproterone also has an effect on the treatment of prostate cancer and as such may confound the overall management of the prostate cancer. In the US megestrol (Megace) may be preferable, but was not used in this trial as it was not available for use in France.
[Articles] Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial: "Hot flushes are the most common complaints reported by men undergoing androgen suppression treatment for prostate cancer. We designed a randomised double-blind trial to compare the efficacy of three drugs, each of which has proven effective for preventing hot flushes in previous studies."